Bedrijf laden
Just reported
Q3 2026 results
From Co.-Diagnostics's results release of 10 november 2026; its quarterly report has since been filed.
Revenue
Actual
US$ 282,9K
+95% y/y
+70% q/qGuided
—
No guide given
EPS, GAAP
Actual
US$ -1,01
Guided
—
No guide given
Operating income, GAAP
Actual
US$ -6,3M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Co.-Diagnostics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Devices
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plcUS$ 129,2BA+
SYKStryker Corp.US$ 118,9BA+
EWEdwards Lifesciences CorporationUS$ 60,9BA+
GEHCGE Healthcare Technologies Inc.US$ 37BA
GKOSGlaukos CorpUS$ 14,6BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 okt 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A- EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
BIIBBiogen Inc.28 okt 2026BAGraded B, now A
Gebouwd uit de eigen deponeringen van Co.-Diagnostics, Inc. bij de Amerikaanse toezichthouder Securities and Exchange Commission (SEC). De cijfers zijn zoals gerapporteerd, met de historie per aandeel herrekend naar de huidige aandelenbasis. Dit beschrijft een bedrijf — het is geen beleggingsadvies en geen aanbeveling om iets te kopen of te verkopen.
